Citations

Clear

35 citation(s) found for "Zhang, Ying".

The Osteogenic Transcription Factor Runx2 Controls Genes Involved in Sterol/Steroid Metabolism, Including Cyp11a1 in Osteoblasts
Teplyuk, Nadiya M., Lou, Yang , Hawse, John R. , Hassan, Mohammad Q., Teplyuk, Viktor I., Pratap, Jitesh , Galindo, Mario , Stein, Janet L. , Stein, Gary S., Lian, Jane B. , Wijnen, André J. van , Zhang, Ying , van Wijnen, Andre J

Mayo Clinic

Molecular Endocrinology | April 3, 2009 | Volume: 23 | Issue: 6 | Pages: 849-861

10.1210/me.2008-0270 | PMID 19342447 Get It

Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
Marlow, Laura A. , Cleland, Alan S., Kurakata, Shinichi, Fujiwara, Kôsaku, Zhang, Ying , Sebo, Thomas, Grant, Clive S., McIver, Bryan, Wadsworth, J. Trad , Smallridge, Robert C., Copland, John A. , Reynolds, Lisa A. , Cooper, Simon JR , Gumz, Michelle L. , Radisky, Derek C. , Marlow, Laura

Mayo Clinic

Cancer Research | February 11, 2009 | Volume: 69 | Issue: 4 | Pages: 1536-1544

10.1158/0008-5472.can-08-3718 | PMID 19208833 Get It

Abstract Anaplastic thyroid carcinoma (ATC) is a highly aggressive form of the disease for which new therapeutic options are desperately needed. Previously, we showed that the high-affinity peroxisome proliferator–activated receptor γ (PPARγ) agonist, RS5444, inhibits cell proliferation of ATC cells via induction of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 (p21). We show here that up-regulation of RhoB is a critical step in PPARγ-mediated activation of p21-induced cell stasis. Using multiple independently derived ATC cell lines, we found that treatment with RS5444 leads to the up-regulation of RhoB and subsequent activation of p21, and that silencing of RhoB by RNAi blocks the ability of RS5444 to induce p21 and to inhibit cell proliferation. Our results show that transcriptional regulation of RhoB by the nuclear transcription factor PPARγ is responsible for the induction of p21 mRNA and protein. We further implicate RhoB as a key signaling effector for the growth inhibition of ATC, as treatment with a histone deacetylase inhibitor shown to increase RhoB expression in lung cancer cells caused the up-regulation of RhoB in ATC cells accompanied by increased expression of p21 and inhibition of cell proliferation; this effect occurred even in ATC cells that were unresponsive to RS5444 due to a lack of expression of PPARγ. Our results implicate RhoB as a novel intermediate in critical signaling pathways and as an additional target for therapeutic intervention in ATC. [Cancer Res 2009;69(4):1536–44]
Neuropilin-1 Upholds Dedifferentiation and Propagation Phenotypes of Renal Cell Carcinoma Cells by Activating Akt and Sonic Hedgehog Axes
Cao, Ying , Nandy, Debashis, Basu, Ananda , Wang, Ling , Zhang, Ying , Radisky, Derek C. , Mukhopadhyay, Debabrata

Mayo Clinic

Cancer Research | October 30, 2008 | Volume: 68 | Issue: 21 | Pages: 8667-8672

10.1158/0008-5472.can-08-2614 | PMID 18974107 Get It

Abstract Expression of neuropilin-1 (NRP-1) has been shown in many cancer cells, but its molecular effect on tumorigenesis is largely unknown. In this report, we show that in aggressive types of renal cell carcinoma (RCC), NRP-1 is expressed at a high level. We show that after knockdown of NRP-1 by short hairpin RNA, RCC cells express significantly lower levels of MDM-2 and p63 proteins but higher levels of p53, and exhibit reduced migration and invasion. When implanted in mice, RCC cells with a reduced NRP-1 level have a statistically significant smaller tumor-forming ability than control cells. Also, NRP-1 knockdown RCC cells exhibit a more differentiated phenotype, as evidenced by the expression of epithelial-specific and kidney-specific cadherins, and the inhibition of sonic hedgehog expression participated in this effect. Inhibition of sonic hedgehog expression can be reversed by ΔNp63α overexpression. Our study reveals that NRP-1 helps maintain an undifferentiated phenotype in cancer cells. [Cancer Res 2008;68(21):8667–72]
Incidence and Risk Factors for Stroke in American Indians
Zhang, Ying , Galloway, James M., Welty, Thomas K. , Wiebers, David O. , Whisnant, Jack P., Devereux, Richard B. , Howard, Barbara V. , Cowan, Linda D., Yeh, Jeunliang, Howard, Wm. James, Lee, Elisa T. , Kizer, Jorge R. , Wang, Wenyu , Best, Lyle G.

Mayo Clinic

Circulation | September 23, 2008 | Volume: 118 | Issue: 15 | Pages: 1577-1584

10.1161/circulationaha.108.772285 | PMID 18809797 Get It

Background— There are few published data on the incidence of fatal and nonfatal stroke in American Indians. The aims of this observational study were to determine the incidence of stroke and to elucidate stroke risk factors among American Indians. Methods and Results— This report is based on 4549 participants aged 45 to 74 years at enrollment in the Strong Heart Study, the largest longitudinal, population-based study of cardiovascular disease and its risk factors in a diverse group of American Indians. At baseline examination in 1989 to 1992, 42 participants (age- and sex-adjusted prevalence proportion 1132/100 000, adjusted to the age and sex distribution of the US adult population in 1990) had prevalent stroke. Through December 2004, 306 (6.8%) of 4507 participants without prior stroke suffered a first stroke at a mean age of 66.5 years. The age- and sex-adjusted incidence was 679/100 000 person-years. Nonhemorrhagic cerebral infarction occurred in 86% of participants with incident strokes; 14% had hemorrhagic stroke. The overall age-adjusted 30-day case-fatality rate from first stroke was 18%, with a 1-year case-fatality rate of 32%. Age, diastolic blood pressure, fasting glucose, hemoglobin A 1c, smoking, albuminuria, hypertension, prehypertension, and diabetes mellitus were risk factors for incident stroke. Conclusions— Compared with US white and black populations, American Indians have a higher incidence of stroke. The case-fatality rate for first stroke is also higher in American Indians than in the US white or black population in the same age range. Our findings suggest that blood pressure and glucose control and smoking avoidance may be important avenues for stroke prevention in this population.
Type III Transforming Growth Factor-β (TGF-β) Receptor Mediates Apoptosis in Renal Cell Carcinoma Independent of the Canonical TGF-β Signaling Pathway
Margulis, Vitaly , Maity, Tapati , Zhang, Xiu-Ying, Copland, John A. , Wood, Christopher G. , Cooper, Simon JR

Mayo Clinic

Clinical Cancer Research | September 15, 2008 | Volume: 14 | Issue: 18 | Pages: 5722-5730

10.1158/1078-0432.ccr-08-0546 | PMID 18794080 Get It

Abstract Purpose: Alterations in transforming growth factor-β (TGF-β) signaling occur early during malignant transformation of renal epithelial cells and are associated with loss of type III TGF-β receptor (TβRIII) expression. We evaluated the role of TβRIII in mediation of apoptosis using in vitro cell culture and in vivo animal models of clear cell renal cell carcinoma. Experimental Design: TβR3 expression was manipulated with adenoviral gene vector delivery system in vitro and in vivo. Induction of apoptosis and signaling through the Smad and mitogen-activated protein kinase (MAPK) pathways were examined at various time points after infection. To study viral oncolysis in vivo, human renal cell carcinoma cells were implanted s.c. in the flanks of nude mice and treated with intratumoral injections of adenovirus. Results: Restoring TβRIII expression in clear cell renal cell carcinoma resulted in a marked induction of apoptosis using in vitro cell culture and in vivo animal models. The expression of the cytoplasmic domain, but not the extracellular domain, of TβRIII mimicked the induction of apoptosis by full-length TβRIII in cell culture and the growth inhibition of tumors in athymic nude mice. TβRIII-associated apoptosis was not dependent on signaling through the canonical TGF-β/Smad pathway but was mediated through p38 MAPK. Conclusion: These findings indicate a novel mechanistic antitumor function for TβRIII and further support its role as an important tumor suppressor in clear cell renal cell carcinoma.